Ionizable Lipid Nanoparticles for Stable Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid delivery systems face challenges such as susceptibility to nuclease digestion in plasma and limited intracellular access, necessitating improved cationic lipids and lipid nanoparticles for effective protection and delivery of therapeutic nucleic acids.
Innovation Solution
Development of novel cationic lipids and lipid nanoparticles, combined with neutral lipids, cholesterol, and polymer conjugated lipids, to form stable nanoparticles that protect nucleic acids from degradation and facilitate intracellular delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If free nucleic acids are administered, then they can reach intracellular targets, but they are susceptible to nuclease digestion in plasma
Solution Approach 1:
Lipid nanoparticles serve as intermediary carriers that protect nucleic acids from plasma nucleases while facilitating cellular uptake. The lipid formulation acts as a protective mediator between the fragile nucleic acid and the hostile plasma environment, preventing degradation without requiring complex engineering of the nucleic acid itself.
Solution Approach 2:
The patent modifies the physical and chemical parameters of nucleic acid delivery by formulating them into lipid nanoparticles with specific size ranges (20-200 nm), charge characteristics (cationic to neutral), and compositional ratios (e.g., 30-70% ionizable lipid, 10-40% phospholipid). These parameter changes enable protection from degradation while maintaining deliverability.
2Reliability
If cationic lipids are used to protect nucleic acids, then plasma stability improves, but cytotoxicity increases
Solution Approach 1:
The patent employs ionizable lipids with pKa values optimized to be cationic at endosomal pH (for membrane disruption and nucleic acid protection) but neutral at physiological pH (reducing cytotoxicity). This dynamic parameter change based on environmental pH resolves the contradiction between protection and toxicity.
Solution Approach 2:
The lipid formulation exhibits different functional properties in different biological compartments: cationic character in the acidic endosome for protection and membrane disruption, neutral character in circulation to minimize off-target toxicity. This spatial variation in chemical properties allows simultaneous achievement of plasma stability and reduced cytotoxicity.
3Reliability
If lipid nanoparticles are formulated for intracellular delivery, then nucleic acid protection improves, but manufacturing complexity increases
Solution Approach 1:
The patent uses pre-formed lipid components (ionizable lipids, phospholipids, cholesterol, PEG-lipids) that can be combined in predetermined ratios to create functional nanoparticles. This preliminary preparation of standardized lipid building blocks simplifies the manufacturing process compared to de novo nanoparticle synthesis, while maintaining intracellular delivery efficiency.
Solution Approach 2:
The lipid nanoparticle formulation combines multiple lipid types in specific ratios (ionizable lipid, phospholipid, cholesterol, PEG-lipid) to achieve complementary functions: nucleic acid complexation, structural integrity, steric stabilization, and cellular uptake. This composite material approach enables robust intracellular delivery through standardized formulation processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel lipid nanoparticles enhance the therapeutic index by providing increased activity and tolerability, ensuring effective intracellular delivery of nucleic acids, including mRNA and oligonucleotides, with improved safety and reduced toxicity.
Implementation Method 1
Lipid nanoparticles formed from cationic lipids with other lipid components have been used to block degradation of the RNAs in plasma and facilitate the cellular uptake of the oligonucleotides
Data Source
AI summary
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein G1, R1, R2, L, and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.